Bioventus entered into a multi-year agreement with Institut Biochimique, gaining exclusive U.S. distribution rights for GELSYN-3™ 3-injection hyaluronic acid product for pain relief associated with knee osteoarthritis. Bioventus plans to launch GELSYN-3 in 3Q16.
GELSYN-3 received FDA premarket approval in 2014; the product is indicated for relief of knee pain for up to 26 weeks.
Source: Bioventus LLC
The agreement supports Bioventus' intent to position itself as an orthobiologics leader. Other entities that compete in the 3-injection space, as summarized in the relevant product landscape in THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT, include Anika, Ferring, Sanofi, Tribute Pharmaceuticals, etc.